Opinion|Videos|October 14, 2024
Interpreting DeLLphi-301 Trial Results: ORR, Duration of Response, and Long-Term Outcomes
Author(s)Joshua K. Sabari, MD
Joshua K. Sabari, MD, discusses how the ORR of 32% to 40% observed in the DeLLphi-301 clinical trial among participants receiving tarlatamab is clinically meaningful, particularly given that these responses occurred between 5 and 7 weeks after initiation and emphasize the importance of ORR as a primary end point in evaluating the efficacy of treatment in this patient population.
Episodes in this series
Video content above is prompted by the following:
Please provide your insights on an ORR of 32% to 40% among participants in the 10-mg and 100-mg groups of the DeLLphi-301 clinical trial.
- How clinically meaningful is an objective response observed between 5 and 7 weeks of tarlatamab initiation?
- Please express your views on selecting ORR as the primary end point in this study.
